Skip to main content


Augie in Loving Memory

Augie Nieto Dies at Age 65

By Champions No Comments

Fitness Industry Mogul, Founder of Augie’s Quest to Cure ALS & Hero to ALS Families


Orange County, CA  (February 24, 2003) — With deep sadness, Augie’s Quest shares the news that its founder, beloved leader and ALS champion, Augie Nieto, died, surrounded by his family on February 22, 2023, just seven days past his 65th Birthday.

Augie was the fitness industry mogul credited for the success of Lifecycle, Life Fitness and Octane Fitness brands.   In 2005, at the height of his career, he was diagnosed with amyotrophic lateral sclerosis, or ALS, a progressive nervous system disease that affects nerve cells in the brain and spinal cord, causing loss of muscle control.

Shortly after his diagnosis, he and his wife Lynne, co-founded Augie’s Quest, a nonprofit laser focused on raising the funds and awareness needed to advance cutting-edge research and fast-track effective treatments to ultimately cure ALS.   With the fierce tenacity he used to revolutionize the modern-day fitness industry, Augie, expended that same high-energy and business acumen to transform how ALS research is conducted today.

Since 2005, under Augie’s leadership, nearly $200 million has been raised for ALS research. These funds helped to establish the Augie’s Quest Translational Research Center at the ALS Therapy Development Institute (ALS TDI) to better understand the mechanisms of how ALS affects the body and use the knowledge to develop new, more effective treatments for the disease. A crowning achievement, Augie’s Quest funding has led to development of Tegoprubart (formerly AT-1501), one of the most promising ALS treatments in development today and marks the very first time in history a non-profit organization research project has reached this stage of drug development.

As a leader in an industry dedicated to maintaining muscle strength and performance, it is tragic irony that Augie’s disease robbed him of the strength and use of his body.  But, ALS could not take away his fierce competitive nature, determination, drive and love of life, friends and family.  A visionary and true hero to so many ALS families, Augie galvanized the global fitness industry, caproate partners, individual donors, ALS families and friends, to join forces to change the way people live with ALS.

In Augie’s own words: “Please keep me in your hearts…please help continue the progress of Augie’s Quest to Cure ALS. Please help Lynne to carry on the mission – the second finest achievement of my life. Because I will be in your heart, I will get to experience the joy when we discover a cure.”

His life story was chronicled in the award-winning film, AugieTo honor of Augie’s memory, visit Augie’s Quest.    

***updated video of Augie’s Celebration



Our Hero Augie Nieto ♥️ February 15, 1958 – February 22, 2023

By Champions No Comments

Augie Nieto was our hero. 
He inspired us, made us laugh, and made us cry. He taught us that when life hands you unspeakable challenges, what really matters is surrounding yourself with people who love you, and a cause you believe in. He was passionate about finding a cure for ALS, and we are proud to be “Augie’s team”.
Augie passed peacefully yesterday surrounded by his beloved wife, Lynne, his family and loved ones.
Augie wrote:
Please keep me in your hearts…please help continue the progress of Augie’s Quest to Cure ALS. Please help Lynne to carry on the mission – the second finest achievement of my life. Because I will be in your heart, I will get to experience the joy when we discover a cure.

Augie was a visionary – an icon in the fitness industry, and a powerful force in the ALS space. He was the Co-Founder and retired CEO of Life Fitness, Chairman and Co-Founder of Augie’s Quest to Cure ALS, and the Chairman of the ALS Therapy Development Institute. He was a beloved husband, father, brother, son, mentor, and friend. Under his leadership, almost $200 million was raised for ALS research. More importantly, Augie was directly responsible for countless advancements and changing the landscape of this horrific disease that ultimately took him just after his 65th birthday.
We were proud to fight with Augie and Lynne to transform the way ALS research is funded, approaching it in unprecedented ways. We will diligently work beside his beloved wife in Augie’s honor and memory to find a cure for ALS.
Augie wrote:
I know that my fight is not over. I have battled ALS for almost 18 years. Physically, ALS has finally taken my body, but my battle to rid the world of this insidious disease will continue.

We love you Augie. We’re with you, Lynne.
Your Augie’s Quest Team
Shannon, Gretchen, Kelly, Angel and Kelsey


Nancy Sallaberry

By Champions No Comments

After a courageous, nearly eight-year battle with ALS, Menlo Park resident Nancy Sallaberry passed peacefully in her home on December 18, 2022. Her devoted husband of 38 years Paul Sallaberry; her three sons Marc, Luc, and Daniel Sallaberry; daughter-in-law Brittany Sallaberry, and grandson Chase, were by her side.

Nancy is survived by her three treasured siblings: brother Ron Williams and his wife Joyce; sister Victoria Evans; and brother Reese Williams and his wife Fran. Nancy also was the beloved sister-in-law of Denise Sallaberry and her husband Peter Wilk, and Jack Sallaberry and his wife Sue, as well as a wonderful aunt to many nieces and nephews.

Nancy was born in Marin County in 1955 to the late Reese and Marge Williams; the family later moved to Saratoga, Calif. where Nancy and her siblings grew up. At Saratoga High School Nancy excelled at five sports, reigned as homecoming queen, and made dear, lifelong friends.  She then attended the University of California, Davis, where she played intercollegiate volleyball and earned a Bachelor of Science degree in Dietetics, complementing her already outstanding culinary skills.  It was at UC-Davis that she met Paul.

Nancy worked for several years in the tech industry at Triad Systems, but she found her true calling as a mother. She was devoted to her three sons and a tireless volunteer in their school and sports programs. Nancy preferred to work behind the scenes, and she was an unsung hero bringing creativity, attention to detail, and 110% effort to any project aimed at enriching an experience for young people in the community.

Nancy also had a lifelong passion for sports and the outdoors. She was a proud and devoted soccer mom, a faithful Giants fan, and a gifted tennis player whose senior doubles team twice reached the USTA’s National Finals. She delighted in fishing and enjoying nature with her boys in Northern California mountain areas such as the Trinity Alps and Hat Creek.

Nancy’s gentle and understanding nature, her deep loyalty, her lively sense of humor, and her sparkling smile were a gift to everyone she knew.  She found so many ways to show love to family and friends, whether with a wonderful meal, a supportive shoulder, the perfect gift, or a wry practical joke.  Not only did Nancy navigate ALS with great dignity, she became a trusted friend and resource to others newly diagnosed with the condition. There is a celebration of Nancy’s life planned for the spring.  The family respectfully requests that anyone interested in honoring Nancy consider a gift to Augie’s Quest, a foundation dedicated to supporting research to cure ALS (



Nancy Sallaberry

Nancy Sallaberry

The Crawford Charity Golf Tournament raises over $226,000 for ALS Research

By Champions, Fundraising Events No Comments

Thanks to the Crawford Family for choosing Augie’s Quest to Cure ALS as the beneficiary of their 2022 golf outing in August. Today, proceeds of $226,295 were granted to fund the Augie’s Quest to Cure ALS Translational Research Center at the ALS Therapy Development institute. 

These funds are part of a larger $5.8 million grant from Augie’s Quest to ALS TDI through 2024 that was established to fund the discovery of new candidate drugs to slow, stop, or even reverse ALS disease progression. It will help to strengthen existing and future research efforts by aiming to dissect mechanisms of clinical ALS, and use the knowledge to develop new, more powerful drug discovery platforms and facilitate more effective drug development for ALS. 

“We’re grateful to the Crawford family for their dedication to funding ALS research,” wrote Augie Nieto, Chairman of Augie’s Quest to Cure ALS. “We know ALS is curable, and the more champions that support our critical mission, the closer we will get to a cure.”

Sponsors from the tournament included the San Francisco Giants, BiRite Foodservice Distributors, Fragomen, Wasserman, the Brandon Crawford Baseball Camp, the Heller Family, the San Francisco 49ers, Pure Storage, Bitwise, Holmes Helping Hands, the Golden State Warriors and Harmony Capital, LLC.  Special thanks to Augie’s Quest to Cure ALS board member Paul Sallaberry and his wife, Nancy, for their sponsorship and involvement in the tournament.  

The highlight of the event was the engagement from those living with ALS.  Thank you to Osiel Mendoza for sharing his story Read it here

Augie’s Quest to Cure ALS granted $159,122 to the ALS Therapy Development Institute through Cure ALS Golf Classic

By Champions No Comments

August 26, 2022: Augie’s Quest to Cure ALS granted $159,122 to the ALS Therapy Development Institute today. Special thanks to Scott Cameron, recipient of the Phil Green award and chairman of the Cure ALS Golf Classic, for playing a key role in raising these research funds, which are granted in his honor. Scott is a member of the Augie’s Quest to Cure ALS Leadership Council and works tirelessly to find treatments and a cure in honor of his late father, Sandy, who had ALS.

“Thank you to Scott Cameron for sharing our Quest to find a cure for ALS, and his continued leadership,” said Augie Nieto, Chairman of Augie’s Quest to Cure ALS.  “With warriors like Scott and his family, we’re closer than ever to a cure.  We’re proud to provide these funds to ALS TDI in honor of the great volunteer work being done by Scott Cameron ,Phil Green and the dedicated event committee.”

These critical funds support the Augie’s Quest Translational Research Center at ALS TDI which was established to better understand the mechanisms of how amyotrophic lateral sclerosis (ALS) affects the body and use the knowledge to develop new, more effective treatments for the disease. These funds are part of a larger $5.8 million grant from Augie’s Quest to ALS TDI through 2024 that was established to fund the discovery of new candidate drugs to slow, stop, or even reverse ALS disease progression.

The Cure ALS Golf Classic has raised more than $1 million for ALS research. 

Augie's Quest logo

ALS Community Comes Together in Unprecedented Fashion To Urge Congress To Pass Critical Access To Disability Benefits Bill

By Champions


Sept. 15, 2020


ALS Community Comes Together in Unprecedented Fashion To Urge Congress To Pass Critical Access To Disability Benefits Bill

Twenty ALS Advocate Groups Coordinate to Attain More than 360 Co-Sponsors

in both the House and Senate


WASHINGTON – This week, twenty ALS advocacy groups collaborated together to thank the more than 360 Congressional members from across the aisle who have co-sponsored H.R. 1407 and S. 578, which would extend Social Security Disability Insurance (SSDI) benefits for patients living with ALS. The ALS community is now calling on Congress for swift passage of H.R. 1407 and S. 578.


The legislation was introduced 19 months ago, but the coordinated campaign among local, regional and national ALS organizations drove progress in the past six months to attain Congressional support. The passing of the bill will provide ALS patients and their loved ones access to SSDI benefits without having to wait five months from the time of diagnosis – an eternity within the two-to-five-year life expectancy of the disease.


The effort was sustained by members of the ALS community who worked with Congress, including:


  • ALS Hope Foundation
  • Answer ALS
  • Augie’s Quest to Cure ALS
  • Brigance Brigade
  • Compassionate Care ALS
  • Every90Minutes Foundation
  • Everything ALS
  • Hope Loves Company
  • I AM ALS
  • Joe Martin ALS Foundation
  • Les Turner ALS Foundation
  • A Life Story Foundation
  • Live Like Lou
  • Muscular Dystrophy Association
  • The Northeast ALS Consortium (NEALS)
  • The Project ALS Therapeutics Core at Columbia
  • Team Stevens Nation
  • Team Gleason
  • Your ALS Guide



The ALS community is grateful to each Representative and Senator supporting H.R. 1407 and S.578 during this critical moment for our nation. ALS is an enormous financial burden and it is crucial those living with ALS and their families have as much support as possible. Now, more than ever, it’s imperative Congress passes H.R. 1407 and S. 578 and sends it to the President’s desk for his signature.


About ALS

ALS is a disease that attacks cells in the body that control movement. It makes the brain stop talking to the muscles, causing increased paralysis over time. Ultimately, ALS patients become prisoners within their own bodies: unable to eat, talk, breathe or move on their own. Their mind, however, often remains sharp so they are aware of what’s happening to them. ALS will affect 1 in 300 people in our lifetimes, and patients usually have no more than two to five years to live following diagnosis.

Augie's Quest logo

Acquisition of Anelixis Therapeutics Fuels Hopes for ALS

By Champions

Acquisition of Anelixis Therapeutics Fuels Hopes for ALS



ORANGE COUNTY, Calif. SEPTEMBER 15, 2020 Anelixis Therapeutics, the for-profit clinical-stage development company that advanced the drug AT-1501 to clinical trial, announced on Monday, September 14, that they have been acquired by Novus Therapeutics. Through this acquisition, AT-1501 is expected to advance to the next stage of clinical development, a phase 2 trial in ALS.

Augie Nieto, the-co-founder and Chairman of Augie’s Quest to Cure ALS also serves as Chairman of the ALS Therapy Development Institute, who invented AT-1501.  Augie was also a founding board member of Anelixis.

“When we started Augie’s Quest to Cure ALS in 2005, we knew our best chance of fueling a cure and treatments for this devastating disease was to find the best scientific partner – which we did in ALS TDI,” said Augie Nieto.  “Solid leadership drives success, and we couldn’t be more excited about the acquisition of Anelixis by Novus Therapeutics.  We need stronger treatment options for ALS, and I’m confident this is a critical step to reach that goal,” he added.

AT-1501 is an investigational antibody that targets the CD40 ligand (CD40L), a protein present at the surface of some white blood cells that is involved in inflammation. In ALS, blocking CD40L activation decreases inflammatory responses implicating CD40L in neurodegeneration.

AT-1501 was invented by the ALS Therapy Development Institute with funding from Augie’s Quest to Cure ALS, and in 2019, Anelixis Therapeutics successfully completed phase 1 clinical trials for AT-1501 as a treatment for ALS. The study, involving both healthy volunteers and participants with ALS, showed that AT-1501 was well tolerated at all doses tested and that the pharmacokinetic properties of AT-1501 were typical for an IgG1 antibody therapeutic.

AT-1501 is being developed by Novus Therapeutics as a potential treatment in renal transplantation, islet cell transplantation, autoimmune nephritis, and ALS . ALS will be the first of these indications to begin enrolling for Phase 2 trials, and enrollment is expected to begin by the end of 2020.

ALS TDI’s CEO, Steve Perrin, PhD stated, “The partnership between ALS TDI and Anelixis to move AT-1501 from preclinical to clinical development has been very exciting. This unique business relationship truly demonstrates the ability of a non-profit to leverage philanthropic support, like that from Augie’s Quest to Cure ALS,  to move a promising treatment into clinical trials. As we discover more potential treatments for ALS, we will lean into these experiences as we look to advance new leads into human clinical testing.”

Steve Perrin will serve as President and Chief Scientific Officer of Novus Therapeutics, and also serve on the board.  Walter Ogier, the Chairman of the Board of Anelixis, will take the second board seat.  “I was so impressed with Walter’s performance as Chairman of Anelixis, that I believed it was critical that Steve and Walter continue to serve on the board due to their decades of experience,” added Nieto.

AT-1501 is the first potential treatment to be invented at ALS TDI and successfully advanced through a Phase 1 clinical study. However, scientists at ALS TDI are continuing to work to find more potential treatments for people with ALS. With continued funding, ALS TDI hopes to develop more promising treatments that can be brought through trial and eventually become available for people with ALS.  Augie’s Quest to Cure ALS is committed to continue to fund the important science being done at ALS TDI.

About Augie’s Quest to Cure ALS

 Augie’s Quest to Cure ALS is dedicated to changing the experience of people living with ALS. We raise the funds and awareness urgently needed to advance cutting-edge research, fast-track effective treatments, and ultimately, find a cure for this devastating disease. Augie’s Quest was founded in 2005 by Augie Nieto, the successful fitness industry mogul behind Lifecycle and Life Fitness and whose life story was recently chronicled in the award-winning film, Augie. With Augie’s Quest, ALS doesn’t stand a fighting chance. Because ALS isn’t incurable, it’s only underfunded. Please join our quest at

About AT-1501

AT-1501 is a humanized IgG1 anti-CD40L antibody with high affinity for CD40L, a well-validated target with broad therapeutic potential. The CD40/CD40L pathway plays a central role in generating pro-inflammatory responses in autoimmune disease, allograft transplant rejection, and neuroinflammation. In a Phase 1 safety study of healthy volunteers and patients with ALS, AT-1501 was well tolerated at all doses tested.


About Anelixis Therapeutics

 Anelixis Therapeutics, Inc. was a clinical stage, privately held biotechnology company developing treatments for patients with neurodegenerative disease, people requiring an organ or cell based transplant, as well as people with an autoimmune disease. Since its founding in 2015, Anelixis Therapeutics has optimized and validated a cGMP manufacturing process for AT-1501, confirmed exceptional activity in preclinical disease models, demonstrated safety and tolerability in humans

The development of AT-1501 has been funded with support from The ALS Therapy Development Institute, Augie’s Quest to Cure ALS, The ALS Association, ALS One, ALS Finding a Cure, and The Congressionally Directed Medical Research Program. Anelixis also conducted several private placement rounds including a round led by  Noble Capital Markets, Inc. (Noble), an investment bank headquartered in Boca Raton Florida, who acted as the exclusive placement agent in a private placement financing round, and a financing round was also led by the Biotechnology Value Fund, L.P. and other affiliates of BVF Partners L.P. (“BVF”).

For more information, please visit the company’s website at










ALS won’t stop and neither will Augie’s Quest

Augie’s Quest to Cure ALS
PO Box #9886
Denver, CO 80209

T: 949-506-1007

Copyright © 2022 Augie's Quest. All Rights Reserved.